Autoimmune And Inflammatory Disorders Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Autoimmune and Inflammatory Disorders

Immune system protects the human body from disease and infection. However incase of autoimmune disease, immune system attacks healthy cells in the body by mistake. There are many systemic disorders with possible involvement of the nervous system with presumed inflammatory and autoimmune pathomechanisms. Abnormal inflammatory response is closely associated with in autoimmune diseases. These inflammations cause impaired functioning, resulting in neurological or psychiatric symptoms. Multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome are some of the most well known neurological diseases induced by abnormal autoimmunity.

The exact cause of immune-system misfire is unknown although some people are more likely to get an autoimmune disease than others. Certain autoimmune diseases, like multiple sclerosis and lupus is hereditary. Not every family member will necessarily have the disease, but they inherit a susceptibility to an autoimmune condition. As the incidence of autoimmune diseases is rising, researchers are also investigating environmental risk factors like infections and exposure to chemicals. Autoimmune disorders of the nervous system may affects both CNS and PNS, including the brain, spinal cord, peripheral nerves, neuromuscular junction and skeletal muscle.

Sub-track

Guillain-Barré syndrome
Autoimmune encephalitis
Myasthenia Gravis
NMO Spectrum Disease
Immune-Mediated Myopathies
Immune-Mediated Neuropathies
Novel Targeted Therapies for Autoimmune Diseases
Antigen-Specific Immunosuppression

Market Analysis: The Autoimmune and Inflammatory Disorders market is set for significant growth from 2025-2030, propelled by advancements in both treatments and diagnostics. The overall therapeutics market is projected to achieve a CAGR between 5.25% and 7.76%, potentially reaching $336.26 billion by 2030. The diagnostics market also anticipates strong growth, with CAGRs from 6.18% to 8.3%, aiming for $8.98 billion by 2031. Key growth drivers include IBD therapeutics (8.25% CAGR), Interferons (8.85% CAGR), and online therapeutic channels (9.61% CAGR). In diagnostics, localized autoimmune diagnostics (9.6% CAGR) and software/informatics (12.15% CAGR) are leading the expansion. These figures underscore the dynamic nature of this crucial healthcare sector.

Tracks